B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.
about
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesCellular immune dysfunction in immune thrombocytopenia (ITP).Sweetened antibodies against humoral autoimmunity: sialylated antibodies are required for IVIg-mediated therapy.Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changesB-cell regulation and its application to transplantation.Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.Targeting B cells and autoantibodies in the therapy of autoimmune diseases.Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects.Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye.Fcγ receptor pathways during active and passive immunization.Biological roles of glycans.The Role and Function of Fcγ Receptors on Myeloid Cells.Anti-retroviral antibody FcγR-mediated effector functions.Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.Salvage therapy with high dose Intravenous Immunoglobulins in acquired Von Willebrand Syndrome and unresponsive severe intestinal bleeding.Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury.Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin.Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation
P2860
Q28069362-BE80A561-19A3-4FE6-B969-144D2C6E5C25Q33409710-997FEB1C-6CBC-46D7-9D2B-0E88FAE996BBQ33414406-55DBAEAE-CBCD-4BCC-9F65-C24859D61149Q34468348-868E7826-AEEC-4B20-83E3-5F8338D7CF0CQ38126085-14313604-4AD6-4DF9-8DB4-0C705FB14D48Q38133405-50A30F3C-2B6C-4804-87DE-ACC57C158CE3Q38207937-B1DF319A-25DC-441D-9463-10A715E38322Q38346284-8A379305-9EBB-4AAB-9D1E-2F7A92145237Q38478867-9493CEAF-6E3F-4AA4-911A-41B6155BAECDQ38615357-25A87F95-A94D-4A81-B904-659005A6F0F5Q38936714-5077BC6A-91DB-43A3-BECB-3361ED850306Q39088502-5A8C7B6A-B1D6-4A6F-8A32-EF61C878ECD9Q39108744-613EBEB4-B6FF-4062-99D0-160A6DC0995FQ39729881-79631C3C-22CF-4917-842A-95E076EBFBA7Q40632061-9F808EE2-0B70-449E-B9F3-F9144A9A0C8AQ41170285-DEE88C42-44AE-4492-92D1-3D7C7A87D13DQ45422267-356946A3-32EC-4E4C-9ADD-00B335CCD906Q50193260-13D0DCE4-4E5A-469A-868E-65D1963E07B9Q57253408-CEE6FD12-BB5E-45B7-90C0-44370B5FB5CE
P2860
B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
B cells and CD22 are dispensab ...... enous immunoglobulins in vivo.
@ast
B cells and CD22 are dispensab ...... enous immunoglobulins in vivo.
@en
type
label
B cells and CD22 are dispensab ...... enous immunoglobulins in vivo.
@ast
B cells and CD22 are dispensab ...... enous immunoglobulins in vivo.
@en
prefLabel
B cells and CD22 are dispensab ...... enous immunoglobulins in vivo.
@ast
B cells and CD22 are dispensab ...... enous immunoglobulins in vivo.
@en
P2093
P2860
P50
P356
P1476
B cells and CD22 are dispensab ...... enous immunoglobulins in vivo.
@en
P2093
Inessa Schwab
Lars Nitschke
Susanne Aschermann
P2860
P304
P356
10.1002/EJI.201242710
P407
P577
2012-10-16T00:00:00Z